Phaseline

Targets › PPP3CA

PPP3CA (Protein phosphatase 3 catalytic subunit alpha): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 4, 1 Phase 3; Immunology; next expected readout Jun 2027.

Calcium-dependent, calmodulin-stimulated protein phosphatase which plays an essential role in the transduction of intracellular Ca(2+)-mediated signals. Many of the substrates contain a PxIxIT motif and/or a LxVP motif. (UniProt, Q08209)

Open in Phaseline: the race on PPP3CA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Aurinia Pharmaceuticalsvoclosporin
Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
PPP3CAPhase 4Lupus NephritisMar 2029
Qilu PharmaceuticalVoclosporin (QL1074)
Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
PPP3CAPhase 3Lupus NephritisJun 2027

Conditions

Lupus Nephritis (4)

Modalities

mixed (1), small molecule (1)

Companies

Aurinia Pharmaceuticals (1) Qilu Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.